1. Corporate presentation January 2014

2. What we do

3. In depth technical expertise

4. Ithaka Track Record Founded in 2000 >200 assignments completed for >90 clients Extensive experience of working with regional development organisations Worked with >25 universities on technology commercialisation 9 university spin-outs created and financed >£40 million funding for clients o Venture capital, corporate deals and grants Technical, commercial & IP evaluations undertaken for >30 organisations Due diligence conducted for 9 investment funds Unrivalled network of contacts

5. Ithaka Team Paul Rodgers Founder & MD, experienced biotech entrepreneur, biomarkers & personalised medicine Richard Cumming Life science product development & marketing (Amersham, GE Healthcare) Paula Wittels Medical devices & diagnostics (Pfizer, Quintiles etc.) AxisJohn Adair Biopharmaceutical R&D (Axis Genetics, Scotgen, Celltech, Searle) Bill Primrose Drug discovery & development (PanTherix, SioKem etc.) Mark Treherne Drug discovery & development (Senexis, Cyclofluidic, BioFocus, Pfizer etc.)

6. Ithaka: University Clients

7. Ithaka: Corporate Clients

8. Typical Assignments Business creation & sourcing finance  CYP Design, Psynova Neurotech & Smart Holograms Technical, commercial and market evaluation  Newcastle University: biofilm prevention  Manchester University: novel medical implant device  King’s College London: novel bone implant materials  De Montfort University: artificial pancreas Due diligence  Apposite Capital, Seventure, Finance Wales & Wellcome Trust Strategic advice  Wellcome Genome Campus, ThermoFisher, Smith & Nephew Management, mentoring & coaching  Scottish Enterprise HGSU, ProteinLogic & Delagua Portfolio review  Bloomsbury Bioseed Fund

9. Case Study: Psynova Neurotech Biomarkers for psychiatric disorders –Potential applications in diagnostics, drug discovery and development Ithaka role –Development of commercial strategy, business plan & securing of finance in 2007 –Paul Rodgers: chairman from 2007 to 2012 Results –University spin-out company 2007 –> £8M investment & grant funding –First diagnostic product launched in 2010 –Commercial deal with Roche Pharmaceuticals Dec 2009 –Acquired by Myriad Genetics 2011

10. Case Study: TRUSTECH Hand held ECG device –For the opportunistic screening for atrial fibrillation in primary care. Atrial fibrillation is a risk factor for stroke and patients at risk of stroke can receive prophylactic anticoagulants. Ithaka role –Preparation of a due diligence report on the commercial potential of the device. –Desk research plus a series of interviews with stakeholders (clinicians and commissioners) in the UK and overseas. Results –TRUSTECH secured innovation funding of £517,000 through the Small Business Research Initiative (SBRI) ‘Stroke competition’ –Work is underway on the development and testing of the device

11. Why Work with Ithaka? Personal experience –Technology commercialisation –New ventures –Fund raising –Growth through strategic partnerships –Across the life science spectrum Multi-disciplinary team approach Unique network of contacts Support tailored to meet the client’s needs